A later study, which used 2 large peptide pools of PLP peptides to stimulate CD4+ and CD8+ T-cell responses, also reported that the frequency of CD8+ PLP-specific T cells was significantly increased in MS patients compared to controls [109]. This evidence concerns the gene CD4 and myeloid sarcoma.